Drug Profile
Research programme: oral insulin analogues - Merrion/Novo Nordisk
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merrion Pharmaceuticals; Novo Nordisk
- Class Insulins
- Mechanism of Action Insulin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus; Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetes-mellitus in Europe (PO)
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in Europe (PO)
- 22 Dec 2010 Early research in Undefined indication in Europe (PO)